Reasons,safety and efficacy analysis for conversion of HAART to TAF/ FTC/BIC among HIV-infected patients  

作　　者：Jiang Xiao Guiju Gao Yi Ding Jialu Li Chengyu Gao Qiuhua Xu Liang Wu Hongyuan Liang Liang Ni Fang Wang Yujiao Duan Di Yang Hongxin Zhao 

机构地区：[1]Clinical and Research Center of AIDS,Beijing Ditan Hospital,Capital Medical University,Beijing 100015,China

出　　处：《Chinese Medical Journal》2023年第24期2931-2937,共7页中华医学杂志（英文版）

基　　金：supported by the Beijing Municipal Administration of Hospitals’Ascent Plan(No.DFL20191802);Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support(No.ZYLX202126);Capital’s Funds for Health Improvement and Research(No.2020-2-2174)

摘　　要：Background:This study aimed to determine the reasons for conversion and elucidate the safety and efficacy of transition to tenofovir alafenamide/emtricitabine/bictegravir sodium(TAF/FTC/BIC)in highly active antiretroviral therapy(HAART)-experienced HIV-infected patients in real-world settings.Methods:We conducted a retrospective cohort study.The treatment conversion rationales,safety,and effectiveness in 1684 HIV-infected patients with previous HAART experience who switched to TAF/FTC/BIC were evaluated at Beijing Ditan Hospital from September 2021 to Auguest 2022.Results:Regimen simplification(990/1684,58.79%)was the most common reason for switching,followed by osteoporosis or osteopenia(375/1684,22.27%),liver dysfunction(231/1684,13.72%),decline in tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat(TAF/FTC/EVG/c)with food restriction(215/1684,12.77%),virological failure(116/1684,6.89%),and renal dysfunction(90/1684,5.34%).In patients receiving non-nucleotide reverse transcriptase inhibitors(NNRTI)-containing regimens,lipid panel changes 1 year after switching indicated a difference of 3.27±1.10 mmol/L vs.3.40±1.59 mmol/L in triglyceride(P=0.014),4.82±0.74 mmol/L vs.4.88±0.72 mmol/L in total cholesterol(P=0.038),3.09±0.70 mmol/L vs.3.18±0.66 mmol/L in low-density lipoprotein(P<0.001),and 0.99±0.11 mmol/L vs.0.95±0.10 mmol/L in high-density lipoprotein(P<0.001).Conversely,among patients receiving booster-containing regimens,including TAF/FTC/EVG/c and lopinavir/ritonavir(LPV/r),lipid panel changes presented decreased trends.We also observed an improved trend in viral load suppression,and alanine transaminase(ALT),aspartate transaminase(AST),estimated glomerular filtration rate(eGFR),and serum creatinine levels after the transition(P<0.001).Conclusion:The transition to TAF/FTC/BIC demonstrated good treatment potency.Furthermore,this study elucidates the motivations behind the adoption of TAF/FTC/BIC in real-world scenarios,providing clinical evidence supporting the stable conversion to TAF/FTC/BIC

关 键 词：HIV Antiretroviral therapy highly active CONVERSION Viral load Efficacy SAFETY 

分 类 号：R512.91[医药卫生—内科学]